{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:30:49Z","timestamp":1791379849080,"version":"4.3.3"},"reference-count":192,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Interferons (IFNs) are key cytokines at the intersection of innate and adaptive immunity. While their antiviral and antitumor roles are well recognized, emerging evidence implicates IFNs\u2014particularly types I, II, and III\u2014in the initiation and progression of autoimmune diseases (ADs). This review synthesizes current data on IFN biology, their immunoregulatory and pathogenic mechanisms, and their contributions to distinct AD phenotypes. We conducted a comprehensive review of peer-reviewed literature on IFNs and autoimmune diseases, focusing on publications indexed in PubMed and Scopus. Studies on molecular pathways, immune cell interactions, disease-specific IFN signatures, and clinical correlations were included. Data were extracted and thematically organized by IFN type, signaling pathway, and disease context, with emphasis on rheumatic and systemic autoimmune disorders. Across systemic lupus erythematosus, rheumatoid arthritis, Sj\u00f6gren\u2019s syndrome, systemic sclerosis, idiopathic inflammatory myopathies, multiple sclerosis, type 1 diabetes, psoriasis, and inflammatory bowel diseases, IFNs were consistently associated with aberrant activation of pattern recognition receptors, sustained expression of interferon-stimulated genes (ISGs), and dysregulated T cell and B cell responses. Type I IFNs often preceded clinical onset, suggesting a triggering role, whereas type II and III IFNs modulated disease course and severity. Notably, IFNs exhibited dual immunostimulatory and immunosuppressive effects, contingent on tissue context, cytokine milieu, and disease stage. IFNs are central mediators in autoimmune pathogenesis, functioning as both initiators and amplifiers of chronic inflammation. Deciphering the context-dependent effects of IFN signaling may inform targeted therapeutic strategies and advance precision immunomodulation in autoimmune diseases.<\/jats:p>","DOI":"10.3390\/biomedicines13102472","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:48:21Z","timestamp":1760420901000},"page":"2472","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Interferons in Autoimmunity: From Loss of Tolerance to Chronic Inflammation"],"prefix":"10.3390","volume":"13","author":[{"given":"Grigore","family":"Mihaescu","sequence":"first","affiliation":[{"name":"Department of Botany and Microbiology, Faculty of Biology, University of Bucharest, 030018 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6384-1822","authenticated-orcid":false,"given":"Gratiela","family":"Gradisteanu Pircalabioru","sequence":"additional","affiliation":[{"name":"Department of Botany and Microbiology, Faculty of Biology, University of Bucharest, 030018 Bucharest, Romania"},{"name":"Research Institute of University of Bucharest, 050663 Bucharest, Romania"},{"name":"eBio-Hub Centre of Excellence in Bioengineering, National University of Science and Technology Politehnica Bucharest, 060042 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2113-0495","authenticated-orcid":false,"given":"Claudiu Natanael","family":"Roznovan","sequence":"additional","affiliation":[{"name":"Department of Botany and Microbiology, Faculty of Biology, University of Bucharest, 030018 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia-Mara","family":"Ditu","sequence":"additional","affiliation":[{"name":"Department of Botany and Microbiology, Faculty of Biology, University of Bucharest, 030018 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela Maria","family":"Comanici","sequence":"additional","affiliation":[{"name":"Department of Preclinical Sciences, Faculty of Medicine, Titu Maiorescu University, 040441 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5674-3810","authenticated-orcid":false,"given":"Octavian","family":"Savu","sequence":"additional","affiliation":[{"name":"\u201cN.C. Paulescu\u201d National Institute of Diabetes, Nutrition and Metabolic Diseases, 020042 Bucharest, Romania"},{"name":"Department of Doctoral School, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 5th District, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Shirafkan, F., Hensel, L., and Rattay, K. (2024). Immune Tolerance and the Prevention of Autoimmune Diseases Essentially Depend on Thymic Tissue Homeostasis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1339714"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s12026-016-8842-6","article-title":"Tolerance, Loss of Tolerance and Regaining Tolerance to Self by Immune-Mediated Events","volume":"65","author":"Barabas","year":"2017","journal-title":"Immunol. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-021-02612-w","article-title":"Impact of the HLA-DRB1 Shared Epitope on Responses to Treatment with Tofacitinib or Abatacept in Patients with Rheumatoid Arthritis","volume":"23","author":"Hirose","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hocking, A.M., and Buckner, J.H. (2022). Genetic Basis of Defects in Immune Tolerance Underlying the Development of Autoimmunity. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.972121"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.adg2992","article-title":"Common Genetic Factors among Autoimmune Diseases","volume":"380","author":"Harroud","year":"2023","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lin, Y.-S., Chang, Y.-C., Pu, T.-Y., Chuang, T.-H., and Hsu, L.-C. (2025). Involvement of Nucleic Acid-Sensing Toll-Like Receptors in Human Diseases and Their Controlling Mechanisms. J. Biomed. Sci., 32.","DOI":"10.1186\/s12929-025-01151-9"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101569","DOI":"10.1016\/j.xcrm.2024.101569","article-title":"Uncoupling Interferons and the Interferon Signature Explains Clinical and Transcriptional Subsets in SLE","volume":"5","author":"Goldman","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13148-017-0378-7","article-title":"Translating Epigenetics into Clinic: Focus on Lupus","volume":"9","author":"Wang","year":"2017","journal-title":"Clin. Epigenet."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pender, M.P., and Burrows, S.R. (2021). Epstein\u2013Barr Virus and Autoimmune Responses in Systemic Lupus Erythematosus. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.587380"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Moulton, V.R. (2018). Sex Hormones in Acquired Immunity and Autoimmune Disease. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02279"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.39560","article-title":"X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased 47,XXX in Systemic Lupus Erythematosus and Sj\u00f6gren\u2019s Syndrome","volume":"68","author":"Liu","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Darrah, E., and Andrade, F. (2013). NETs: The Missing Link between Cell Death and Systemic Autoimmune Diseases?. Front. Immunol., 3.","DOI":"10.3389\/fimmu.2012.00428"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrg.2015.33","article-title":"Autoimmune Diseases\u2014Connecting Risk Alleles with Molecular Traits of the Immune System","volume":"17","author":"Rich","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Updated Assessment of the Prevalence, Spectrum and Case Definition of Autoimmune Disease","volume":"11","author":"Hayter","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Goris, A., and Liston, A. (2012). The Immunogenetic Architecture of Autoimmune Disease. Cold Spring Harb. Perspect. Biol., 4.","DOI":"10.1101\/cshperspect.a007260"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"351732","DOI":"10.1155\/2015\/351732","article-title":"Selected Aspects in the Pathogenesis of Autoimmune Diseases","volume":"2015","author":"Nagy","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"108361","DOI":"10.1016\/j.clim.2020.108361","article-title":"Common Innate Pathways to Autoimmune Disease","volume":"212","author":"Langan","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","article-title":"Cytokine Regulation and Function in T Cells","volume":"39","author":"Dong","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41577-024-01040-6","article-title":"A Guide to Adaptive Immune Memory","volume":"24","author":"Lam","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coi.2018.01.002","article-title":"The Regulation of Lymphocyte Activation and Proliferation","volume":"51","author":"Heinzel","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2015.05.010","article-title":"T Helper 2 (Th2) Cell Differentiation, Type 2 Innate Lymphoid Cell (ILC2) Development and Regulation of Interleukin-4 (IL-4) and IL-13 Production","volume":"75","author":"Zhu","year":"2015","journal-title":"Cytokine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1084\/jem.20122759","article-title":"IL-2 Coordinates IL-2-Producing and Regulatory T Cell Interplay","volume":"210","author":"Amado","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e20230063","DOI":"10.1084\/jem.20230063","article-title":"Commensal Bacteria Promote Type I Interferon Signaling to Maintain Immune Tolerance in Mice","volume":"221","author":"Hsu","year":"2024","journal-title":"J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/2326-6066.CIR-16-0193","article-title":"Regulatory T Cells: Differentiation and Function","volume":"4","author":"Plitas","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ciurkiewicz, M., Herder, V., and Beineke, A. (2020). Beneficial and Detrimental Effects of Regulatory T Cells in Neurotropic Virus Infections. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051705"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Liu, S., Zhang, B., Qiao, L., and Zhang, Y. (2020). T Cell Dysfunction and Exhaustion in Cancer. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00017"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102526","DOI":"10.1016\/j.autrev.2020.102526","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: A systematic review","volume":"19","author":"Park","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"986789","DOI":"10.1155\/2013\/986789","article-title":"Th17 cells in immunity and autoimmunity","volume":"2013","author":"Bedoya","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00281-019-00733-8","article-title":"The pathogenicity of Th17 cells in autoimmune diseases","volume":"41","author":"Yasuda","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Belpaire, A., Naves, R., Goebeler, M., Schmidt, A., and Kerstan, A. (2022). From IL-17 to IFN-\u03b3 in Inflammatory Skin Disorders: Is Transdifferentiation a Potential Treatment Target?. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.932265"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev-immunol-082223-044122","article-title":"Molecular Mechanisms Governing CD8 T Cell Differentiation and Function","volume":"43","author":"Rausch","year":"2025","journal-title":"Annu. Rev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bailey, S.R., Nelson, M.H., Himes, R.A., Li, Z., Mehrotra, S., and Paulos, C.M. (2014). Th17 cells in cancer: The ultimate identity crisis. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00276"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/cei\/uxac090","article-title":"Cytokine Production by Human B Cells: Role in Health and Autoimmune Disease","volume":"210","author":"Jebson","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.4049\/jimmunol.172.6.3422","article-title":"Distinct Profiles of Human B Cell Effector Cytokines: A Role in Immune Regulation?","volume":"172","author":"Duddy","year":"2004","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","article-title":"Distinct Effector Cytokine Profiles of Memory and Na\u00efve Human B Cell Subsets and Implication in Multiple Sclerosis","volume":"178","author":"Duddy","year":"2007","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fousert, E., Toes, R., and Desai, J. (2020). Neutrophil Extracellular Traps (NETs) Take the Central Stage in Driving Autoimmune Responses. Cells, 9.","DOI":"10.3390\/cells9040915"},{"key":"ref_37","first-page":"460","article-title":"Origin and Functions of Tissue Macrophages","volume":"40","author":"Epelman","year":"2014","journal-title":"Immunity"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2019.06.009","article-title":"The contribution of Macrophages to SLE pathogenesis","volume":"207","author":"Ma","year":"2019","journal-title":"Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ma, W.-T., Gao, F., Gu, K., and Chen, D.-K. (2019). The Role of Monocytes and Macrophages in AI Disease: A comprehensive Review. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01140"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1136\/annrheumdis-2018-213648","article-title":"Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis","volume":"77","author":"Soldano","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/ni.3710","article-title":"Opposing macrophage polarization programs show extensive epigenomic and transcriptional cross-talk","volume":"18","author":"Piccolo","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/imm.12910","article-title":"Implications of macrophage polarization in autoimmunity","volume":"154","author":"Funes","year":"2018","journal-title":"Immunology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sakowska, J., Arcimowicz, \u0141., Jankowiak, M., Papak, I., Markiewicz, A., Dziubek, K., Kurkowiak, M., Kote, S., Ka\u017amierczak-Siedlecka, K., and Po\u0142om, K.t. (2022). Autoimmunity and Cancer. Two sides of the same coin. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.793234"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.4049\/jimmunol.1301843","article-title":"TGF-\u03b2: Guardian of T Cell Function","volume":"191","author":"AOh","year":"2013","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.32607\/20758251-2019-11-4-4-12","article-title":"Contribution of CMH II genes to an association with AI diseases","volume":"11","author":"Zakharova","year":"2019","journal-title":"Acta Naturae"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2014.08.005","article-title":"Molecular Mechanisms for contribution of MHC molecules to AI diseases","volume":"31","author":"Sollid","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Elkoshi, Z. (2022). Cancer and Autoimmune disease. A tale of Two Immunological Opposites. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.821598"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/JIR.S249384","article-title":"High Treg inflammations promote (most) non-Hematologic Cancers, while low Treg inflamation promote Lymphoid Cancer","volume":"13","author":"Elkoshi","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/JIR.S227279","article-title":"The binary Classification of Chronic Diseases","volume":"12","author":"Elkoshi","year":"2019","journal-title":"J. Inflamm. Res."},{"key":"ref_50","unstructured":"Tak, W., and Saunders, M.E. (2005). Immunity to Pathogens. The Immune Response: Basic and Clinical Principles, Academic Press."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: What do they all do?","volume":"6","author":"Schoggins","year":"2019","journal-title":"Ann. Rev. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1372494","DOI":"10.1155\/2020\/1372494","article-title":"Human type I IFN Antiviral Effects in Respiratory and reemerging viral infections","volume":"2020","author":"Acosta","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/s41467-022-28645-6","article-title":"Identification and Establishment of Type IV Interferon and the Characterization of Interferon-\u03c5 including Its Class II Cytokine Receptors IFN-\u03c5R1 and IL-10R2","volume":"13","author":"Chen","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bbadis.2014.04.030","article-title":"Interferon Regulatory Factors: At the Crossroads of Immunity, Metabolism, and Disease","volume":"1852","author":"Zhao","year":"2015","journal-title":"Biochim. Biophys. Acta\u2014Mol. Basis Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1126\/science.1233321","article-title":"Interferon-\u03b5 Protects the Female Reproductive Tract from Viral and Bacterial Infection","volume":"339","author":"Fung","year":"2013","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1089\/vim.2023.0044","article-title":"Effects of AIM2 and IFI16 on Infectious Diseases and Inflammation","volume":"36","author":"Fan","year":"2023","journal-title":"Viral Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2005-07-2709","article-title":"Specialization kinetics and repertoire of IFN I responses by human plasmacitoid predendritic cells","volume":"107","author":"Ito","year":"2006","journal-title":"Blood."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"104811","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Vlachogianis, N.I. (2020). Association between DNA Damage Response, Fibrosis and Type I IFN signature in SSc. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.582401"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and Distinct Functions of type I and type III IFNs","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2017.04.025","article-title":"Interferon-\u03bb Mediates Non-Redundant Frontline Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness","volume":"46","author":"Galani","year":"2017","journal-title":"Immunity"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7944","DOI":"10.1073\/pnas.1100552108","article-title":"IFN-\u03bb determines the intestinal epithelial antiviral host defense","volume":"108","author":"Pott","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1128\/JVI.00272-10","article-title":"Lambda Interferon Renders Epithelial Cells of the Respiratory and Gastrointestinal Tracts Resistant to Viral Infections","volume":"84","author":"Mordstein","year":"2010","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Santer, D.M., Minty, G.E., Golec, D.P., Lu, J., May, J., Namdar, A., Shah, R.R., Puchta, A., Pelletier, A.R., and Oliveira, A.C. (2020). Differential Expression of IFN-\u03bb Receptor Regulates the Antiviral Activity of Type III Interferons against Enteric Viruses. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008515"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"155637","DOI":"10.1016\/j.cyto.2021.155637","article-title":"Between immunomodulation and immunotolerance: The role of IFN\u03b3 in SARS-CoV-2 disease","volume":"146","author":"Whitfield","year":"2021","journal-title":"Cytokine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cyto.2014.10.014","article-title":"IFN-\u03b3 in Autoimmunity: A Complicated Player on a Complex Stage","volume":"74","author":"Lees","year":"2015","journal-title":"Cytokine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1002\/stem.1799","article-title":"Type II IFN promotes differential of myeloid-biased hematopoietic stem cells","volume":"32","author":"Matatall","year":"2014","journal-title":"Stem Cells"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Nan, Y., Wu, C., and Zhang, Y.-J. (2017). Interplay between Janus Kinase\/Signal Transducer and Activator of Transcription Signaling Activated by Type I Interferons and Viral Antagonism. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01758"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1158\/1541-7786.MCR-14-0450","article-title":"IFN receptor signaling in malignancy","volume":"12","author":"Fish","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e23633","DOI":"10.4161\/jkst.23633","article-title":"STAT: A shape shifting anti-viral super STAT","volume":"2","author":"Choudhury","year":"2013","journal-title":"Jak-Stat"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Tan, P.H., Goh, C.Q., and Chua, J.J.E. (2022). Emerging Roles of Type I Interferons in Neuroinflammation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214394"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Majoros, A., Platanitis, E., Kernbauer-H\u00f6lzl, E., Rosebrock, F., M\u00fcller, M., and Decker, T. (2017). Canonical and Noncanonical Aspects of JAK\u2013STAT Signaling: Lessons from Interferons for Cytokine Responses. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00029"},{"key":"ref_73","first-page":"483","article-title":"The IFNs and their receptors","volume":"90","author":"Weerd","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Low, Z.Y. (2022). SARS-CoV-2, NS proteins and their roles in host immune evasion. Viruses, 14.","DOI":"10.3390\/v14091991"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Rashid, F., Dzakah, E.E., Wang, H., and Tang, S. (2022). Roles and Functions of SARS-CoV-2 Proteins in Host Immune Evasion. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.940756"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cell.2018.09.045","article-title":"The Human Transcription Factors","volume":"175","author":"Lambert","year":"2018","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"105526","DOI":"10.1016\/j.isci.2022.105526","article-title":"Survivin Promotes a Glycolytic Switch in CD4+ T Cells","volume":"25","author":"Erlandsson","year":"2022","journal-title":"iScience"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I IFN responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Ostrycharz, E., and Hukowska-Szematowicz, B. (2022). Host miRNA signature in viral Infections in humans. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810536"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Forster, S.C., Tate, M.D., and Hertzog, P.J. (2015). MicroRNA as type I IFN-regulated transcripts and modulators of innate immune response. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00334"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I Interferon in the Pathogenesis of Systemic Lupus Erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41423-024-01167-5","article-title":"The Role of Plasmacytoid Dendritic Cells (pDCs) in Immunity during Viral Infections and Beyond","volume":"21","author":"Ngo","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e2411747121","DOI":"10.1073\/pnas.2411747121","article-title":"cGAS Activation in Classical Dendritic Cells Causes Autoimmunity in TREX1-Deficient Mice","volume":"121","author":"Li","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1016\/j.cell.2025.06.044","article-title":"Interferons in Health and Disease","volume":"188","author":"Boehmer","year":"2025","journal-title":"Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.4049\/jimmunol.2000596","article-title":"The Role of Cutaneous Type I Interferons in Autoimmune and Autoinflammatory Diseases","volume":"205","author":"Turnier","year":"2020","journal-title":"J. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","article-title":"Epithelial\u2013Immune Cell Interplay in Primary Sj\u00f6gren Syndrome Salivary Gland Pathogenesis","volume":"17","author":"Verstappen","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/BOR.0000000000000907","article-title":"Type 1 Interferon Activation in Systemic Sclerosis: A Biomarker, a Target or the Culprit","volume":"34","author":"Kakkar","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_88","first-page":"e1193","article-title":"Identification of Distinctive Interferon Gene Signatures in Different Types of Myositis","volume":"93","author":"Derfoul","year":"2019","journal-title":"Neurology"},{"key":"ref_89","first-page":"269","article-title":"Interferon-\u03b2 Corrects Massive Gene Dysregulation in Multiple Sclerosis: Short-Term and Long-Term Effects on Immune Regulation and Neuroprotection","volume":"49","author":"Feng","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Newby, B.N., and Mathews, C.E. (2017). Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00232"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1016\/j.cell.2024.10.010","article-title":"Type III Interferons Induce Pyroptosis in Gut Epithelial Cells and Impair Mucosal Repair","volume":"187","author":"Jena","year":"2024","journal-title":"Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","article-title":"The Type I Interferonopathies: 10 Years on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I IFN in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-Inducible Gene Expression Signature in Peripheral Blood Cells of Patients with Severe Lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"17609","DOI":"10.1073\/pnas.1209724109","article-title":"Precise Probes of Type II Interferon Activity Define the Origin of Interferon-Stimulated Genes Induced in Systemic Lupus Erythematosus","volume":"109","author":"Hall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/2211068215589580","article-title":"The Simoa HD-1 Analyzer: A Novel Fully Automated Digital Immunoassay Analyzer with Single-Molecule Sensitivity and Multiplexing","volume":"21","author":"Wilson","year":"2016","journal-title":"J. Lab. Autom."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Del Papa, N., Minniti, A., Lorini, M., Carbonelli, V., Maglione, W., Pignataro, F., Montano, N., Caporali, R., and Vitali, C. (2021). The Role of Interferons in the Pathogenesis of Sj\u00f6gren\u2019s Syndrome. Biomolecules, 11.","DOI":"10.3390\/biom11020251"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Chasset, F., and Arnaud, L. (2021). Type I Interferons in Systemic Autoimmune Diseases. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.633821"},{"key":"ref_100","first-page":"e002864","article-title":"Association between Type I Interferon Pathway Activation and Clinical Features in Rheumatoid Arthritis","volume":"8","year":"2022","journal-title":"RMD Open"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12016-020-08798-2","article-title":"Type I IFNs in Pathogenesis and Treatment of AI diseases","volume":"59","author":"Jiang","year":"2020","journal-title":"Clinic Rev. Allerg. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Raftopoulou, S., Triantafyllopoulou, A., and Mavragani, C.P. (2022). The Role of Type I Interferons in Autoimmune and Autoinflammatory Diseases with CNS Involvement. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.1026449"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ana.410150109","article-title":"A progressive familial encephalopathy with calcification of basal ganglia and chronic cerebrospinal fluid lymphocytosis","volume":"15","author":"Aicardi","year":"1984","journal-title":"Ann. Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.4049\/jimmunol.0902199","article-title":"A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Type I Interferons","volume":"184","author":"Denny","year":"2010","journal-title":"J. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41392-021-00764-4","article-title":"Signaling Pathways in the Regulation of Cytokine Release Syndrome in Human Diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_106","first-page":"1213","article-title":"Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases","volume":"72","author":"Barturen","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jid.2021.11.031","article-title":"Type I IFNs in autoimmunity","volume":"142","author":"Niewold","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1038\/s41467-020-19918-z","article-title":"Functionally Impaired Plasmacytoid Dendritic Cells and Non-Haematopoietic Sources of Type I Interferon Characterize Human Autoimmunity","volume":"11","author":"Psarras","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/sji.12449","article-title":"Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies","volume":"84","author":"Ekholm","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Musella, M. (2021). The Yin and Yang of type I IFNs in Cancer promotion and Immune activatin. Biology, 10.","DOI":"10.3390\/biology10090856"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Platanias, E., and Decker, T. (2018). Regulation networks involving STATs, IFNs and NF-kB in inflammation. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02542"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: Risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41584-021-00606-1","article-title":"IFN \u03bb in inflamation and AI Rheumatic diseases","volume":"17","author":"Goel","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e144918","DOI":"10.1172\/JCI144918","article-title":"Bite of the wolf: Innate immune response propagate autoimmunity in lupus","volume":"131","author":"Gupta","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e000336","DOI":"10.1136\/lupus-2019-000336","article-title":"Type I IFNs in host defense and inflammatory diseases","volume":"6","author":"Crow","year":"2019","journal-title":"Lupus Sci. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon Target-Gene Expression and Epigenomic Signatures in Health and Disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-immunol-031210-101303","article-title":"Chromatin Contributions to the Regulation of Innate Immunity","volume":"32","author":"Smale","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3899\/jrheum.2022-0827","article-title":"Type I Interferons in Autoimmunity","volume":"50","author":"Londe","year":"2023","journal-title":"J. Rheumatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12969-024-00953-9","article-title":"Lymphocyte Apoptosis and Its Association with Disease Severity in Juvenile Systemic Lupus Erythematosus","volume":"22","author":"Eissa","year":"2024","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10067-004-0972-x","article-title":"Lymphocyte Apoptosis and Macrophage Function: Correlation with Disease Activity in Systemic Lupus Erythematosus","volume":"24","author":"Ou","year":"2005","journal-title":"Clin. Rheumatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00296-023-05346-x","article-title":"Systemic Lupus Erythematosus: Latest Insight into Etiopathogenesis","volume":"43","author":"Akhil","year":"2023","journal-title":"Rheumatol. Int."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/art.23619","article-title":"Age- and Sex-Related Patterns of Serum Interferon-\u03b1 Activity in Lupus Families","volume":"58","author":"Niewold","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13075-023-03010-0","article-title":"Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: A retrospective longitudinal analysis","volume":"25","author":"Miyachi","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Antiochos, B., and Rosen, L.C. (2023). Interferon and Autoantigens: Intersection in Autoimmunity. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1165225"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Nandokumar, K.S., and Nundel, K. (2022). Editorial: SLE predisposition factors. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1118180"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jbspin.2009.03.012","article-title":"IFNs and Autoimmune disorders","volume":"17","author":"Meyer","year":"2009","journal-title":"Jt. Bone Spine"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Caneparo, V., Landolfo, S., Gariglio, M., and De Andrea, M. (2018). The Absent in Melanoma 2-Like Receptor IFN-Inducible Protein 16: A Key Player in Innate Immunity, Viral Infection, and Tumorigenesis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01180"},{"key":"ref_128","first-page":"33","article-title":"The Role of NETosis in Systemic Lupus Erythematosus","volume":"1","author":"Ryan","year":"2019","journal-title":"J. Cell. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1089\/jir.2011.0101","article-title":"Interferons in Autoimmune and Inflammatory diseases","volume":"31","author":"Choubey","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13075-019-1878-y","article-title":"High Levels of Circulating Interferons Type I, II and III Associate with Distinct Clinical Features of Systemic Lupus Erythematosus","volume":"21","author":"Oke","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","article-title":"Altered Type II Interferon Precedes Autoantibody Accrual and Elevated Type I Interferon Activity Prior to Systemic Lupus Erythematosus Classification","volume":"75","author":"Munroe","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Sim, T.M., Ong, S.G., and Ling, G.S. (2022). Type I Interferons in Systemic Lupus Erythematosus. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052505"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Karle, C., and Burkhardt, H. (2023). Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054296"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3109\/s10165-012-0811-x","article-title":"The Roles of Interferon-\u03b3 versus Interleukin-17 in the Pathogenic Effects of Human Th17 Cells","volume":"23","author":"Kato","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7555\/JBR.33.20190075","article-title":"Contribution of Neutrophils in the Pathogenesis of Rheumatoid Arthritis","volume":"34","author":"Zhang","year":"2019","journal-title":"J. Biomed. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.it.2008.07.002","article-title":"How IFN\u03b3 keeps Autoimmune diseases in check","volume":"29","author":"Kelchtermans","year":"2008","journal-title":"Trends Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.4049\/jimmunol.158.11.5507","article-title":"Accelerated Collagen-Induced Arthritis in IFN-\u03b3 Receptor-Deficient Mice","volume":"158","author":"Vermeire","year":"1997","journal-title":"J. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN Pathways and Plasmacytoid Dendritic Cell Recruitment in Target Organs of Primary Sj\u00f6gren\u2019s Syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sj\u00f6gren\u2019s Syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and Type II Interferon Signatures in Sj\u00f6gren\u2019s Syndrome","volume":"63","author":"Nezos","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12865","article-title":"Expression of Type III Interferons (IFN-\u03bb) and Their Receptor in Sj\u00f6gren\u2019s Syndrome","volume":"186","author":"Apostolou","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41584-019-0212-z","article-title":"Involvement of the Myeloid Cell Compartment in Fibrogenesis and Systemic Sclerosis","volume":"15","author":"Kania","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40674-021-00188-9","article-title":"Dysregulation of Type I IFN signaling in SSc","volume":"7","author":"Wu","year":"2021","journal-title":"Curr. Treat. Opt. Rheumatol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Wu, M., and Assassi, S. (2013). The Role of type I IFN in Systemic sclerosis. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00266"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/art.41697","article-title":"A Cytokine Network Profile Delineates a Common Th1\/Type 1 B Effector Cell Signature in Autoimmune Diseases","volume":"73","author":"Simon","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/ng1782","article-title":"A Common Haplotype of Interferon Regulatory Factor 5 (IRF5) Is Associated with Increased Risk of Systemic Lupus Erythematosus","volume":"38","author":"Graham","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"154635","DOI":"10.1016\/j.cyto.2018.12.018","article-title":"Type I IFN dysregulation in systemic sclerosis","volume":"132","author":"Skaug","year":"2020","journal-title":"Cytokine."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Valenzi, E., Bulik, M., Tabib, T., Morse, C., Sembrat, J., Trejo Bittar, H.E., Rojas, M., and Lafyatis, R. (2021). Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Lung Fibrosis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.595811"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00439-019-02092-8","article-title":"MX genes. Host determinants controlling influenza virus infection","volume":"139","author":"Haller","year":"2019","journal-title":"Hum. Genet."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00005-019-00564-3","article-title":"Type III Interferons (Lambda Interferons) in Rheumatic Autoimmune Diseases","volume":"68","year":"2020","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Manivasagam, S., and Klein, R.S. (2021). Type III Interferons: Emerging Roles in Autoimmunity. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.764062"},{"key":"ref_152","unstructured":"Basyal, B., Sharma, M., and Goosenberg, E. (2025, August 17). Autoimmune Pancreatitis, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560769\/."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.7150\/ijms.61973","article-title":"Role of Interferon Regulatory Factor-Mediating Signaling in Psoriasis","volume":"18","author":"Wang","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Zhang, L.-J. (2019). Type I Interferons: Potential Initiating Factors Linking Skin Wounds with Psoriasis Pathogenesis. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01440"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Mylonas, A., and Conrad, C. (2018). Psoriazis: Classical and paradoxical. The Yin and Yang of TNF and type I IFN. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02746"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"204ra129","DOI":"10.1126\/scitranslmed.3006245","article-title":"IL-29 Is Produced by TH17 Cells and Mediates the Cutaneous Antimicrobial Defense in Psoriasis","volume":"5","author":"Wolk","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_157","first-page":"e41120","article-title":"Advancements in Inflammatory Bowel Disease: A Narrative Review of Diagnostics, Management, Epidemiology, Prevalence, Patient Outcomes, Quality of Life, and Clinical Presentation","volume":"15","author":"Muzammil","year":"2023","journal-title":"Cureus"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Wallace, J.V., Constant, D.A., Meiss, G., and Pekow, J. (2021). Interferon-\u03bb in the Pathogenesis of Inflammatory Bowel Disease. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.767505"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1101\/sqb.2013.78.020321","article-title":"The IRF Family Transcription Factors at the Interface of Innate and Adaptive Immune Response","volume":"78","author":"Ikushima","year":"2013","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Ottum, P.A., Arellano, G., Reyes, L.I., Iruretagoyena, M., and Naves, R. (2015). Opposing Roles of Interferon-\u03b3 on Cells of the Central Nervous System in Autoimmune Neuroinflammation. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00539"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Arellano, G., Ottum, P.A., Reyes, L.I., Burgos, P.I., and Naves, R. (2015). Stage-Specific Role of Interferon-\u03b3 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00492"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis\u2014A review","volume":"26","author":"Dobson","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1177\/1352458519950101038","article-title":"Effect of Interferon-\u03b3 on T Lymphocytes from Patients with Multiple Sclerosis","volume":"1","author":"Grimaldi","year":"1995","journal-title":"Mult. Scler. J."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ircmb.2021.02.011","article-title":"Type I Interferons as Key Players in Pancreatic \u03b2-Cell Dysfunction in Type 1 Diabetes","volume":"359","author":"Marroqui","year":"2021","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/db07-1331","article-title":"HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk: Analysis of the Type 1 Diabetes Genetics Consortium Families","volume":"57","author":"Erlich","year":"2008","journal-title":"Diabetes"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Gal-Ben-Ari, S., Barrera, I., Ehrlich, M., and Rosenblum, K. (2019). PKR: A Kinase to Remember. Front. Mol. Neurosci., 11.","DOI":"10.3389\/fnmol.2018.00480"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1074-7613(00)00014-5","article-title":"Essential Role for the dsRNA-Dependent Protein Kinase PKR in Innate Immunity to Viral Infection","volume":"13","author":"Balachandran","year":"2000","journal-title":"Immunity"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2018.08.003","article-title":"Interferon-\u03b1: The Key Trigger of Type 1 Diabetes","volume":"94","author":"Lombardi","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"eabd6527","DOI":"10.1126\/sciadv.abd6527","article-title":"Islet Expression of Type I Interferon Response Sensors Is Associated with Immune Infiltration and Viral Infection in Type 1 Diabetes","volume":"7","author":"Apaolaza","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_170","unstructured":"Delves, P.J., and Roitt, I.M. (1998). Insulin-Dependent Diabetes Mellitus, Human. Encyclopedia of Immunology, Academic Press. [2nd ed.]."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"De George, D.J. (2023). Inflammation versus regulation: How IFN\u03b3 contributes to type 1 diabetes pathogenesis. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1205590"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-\u03b1 and IFN\u03b3 Triggers Inflammatory cells death, tissue damage and mortality in SARS-CoV-2 infection","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12967-025-06184-0","article-title":"Systemic lupus erythematosus therapies: A decade of progress and prospects in clinical trials","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"101975","DOI":"10.1016\/j.berh.2024.101975","article-title":"Interferonopathies: From concept to clinical practice","volume":"38","year":"2024","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s10875-024-01660-6","article-title":"Interface Gain-of-Function Mutations in TLR7 Cause Systemic and Neuro-Inflammatory Disease","volume":"44","author":"David","year":"2024","journal-title":"J. Clin. Immunol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/TA.0000000000002214","article-title":"Anti-interferon-\u03b1 receptor 1 antibodies attenuate inflammation and organ injury following hemorrhagic shock","volume":"86","author":"Cagliani","year":"2019","journal-title":"J. Trauma. Acute Care Surg."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Han, J., Suh, C.H., Jung, J.Y., Kim, H.-A., and Lee, S.-K. (2017). Elevated Circulating Levels of the Interferon-\u03b3\u2013Induced Chemokines Are Associated with Disease Activity and Cutaneous Manifestations in Adult-Onset Still\u2019s Disease. Sci. Rep., 7.","DOI":"10.1038\/srep46652"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/1744666X.2023.2268284","article-title":"Anifrolumab: First Biologic Approved in the EU Not Restricted to Patients with a High Degree of Disease Activity for the Treatment of Moderate to Severe Systemic Lupus Erythematosus","volume":"20","author":"Gensous","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/13543784.2020.1797677","article-title":"Type I Interferon Antagonists in Clinical Development for Lupus","volume":"29","author":"Paredes","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"103649","DOI":"10.1016\/j.autrev.2024.103649","article-title":"Tyrosine Kinase 2 Inhibitors in Autoimmune Diseases","volume":"23","author":"Ramakrishna","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7224\/1537-2073.2018-063","article-title":"Interferons in the Treatment of Multiple Sclerosis","volume":"22","author":"Filipi","year":"2020","journal-title":"Int. J. MS Care"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and Type III Interferons\u2014Induction, Signaling, Evasion, and Application to Combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_185","first-page":"575","article-title":"Emerging Concepts of Type I Interferons in SLE Pathogenesis and Therapy","volume":"18","author":"Psarras","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.autrev.2017.11.009","article-title":"Targeting Interferons and Their Pathways in Systemic Lupus Erythematosus","volume":"17","author":"Chasset","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2020.1812201","article-title":"Anifrolumab, a Monoclonal Antibody to the Type I Interferon Receptor Subunit 1, for the Treatment of Systemic Lupus Erythematosus: An Overview from Clinical Trials","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod. Rheumatol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/imt-2016-0090","article-title":"Targeting the Interferon Pathway with Sifalimumab for the Treatment of Systemic Lupus Erythematosus","volume":"9","author":"Greth","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II Study of the Efficacy and Safety of Rontalizumab (rhuMAb Interferon-\u03b1) in Patients with Systemic Lupus Erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/imt-2023-0086","article-title":"The Development of Litifilimab (BIIB 059) for Cutaneous and Systemic Lupus Erythematosus","volume":"16","author":"Cho","year":"2024","journal-title":"Immunotherapy"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/13543776.2025.2477486","article-title":"Challenges, Opportunities, and Therapeutic Potential of JAK Inhibitors and Their Derived PROTACs (2022\u20132023)","volume":"35","author":"Shah","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Bang, C.H., Park, C.J., and Kim, Y.S. (2025). The Expanding Therapeutic Potential of Deucravacitinib beyond Psoriasis: A Narrative Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14051745"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2472\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T06:20:58Z","timestamp":1760422858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":192,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["biomedicines13102472"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13102472","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]}}}